Search results for "Lonidamine"

showing 1 items of 1 documents

Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: A phase II study of the Southern Italy Oncology G…

1998

Lonidamine (LND) is a unique antineoplastic drug derived from indazole-3-carboxylic acid which inhibits oxygen consumption and aerobic glycolysis, interfering with energy metabolism of neoplastic cells. LND has been experimentally shown to potentiate the cytotoxic effects of epirubicin (EPI) in human breast cancer cell lines, cisplatin activity in both platinum-sensitive and -resistant human ovarian carcinoma cell lines, and EPI antineoplastic activity in some recent phase III trials carried out in advanced breast cancer. A multicenter phase II trial was carried out with the combination of cisplatin 60 mg/m2, EPI 100 mg/m2 and LND 450 mg/day p.o. in three refracted doses/day starting 2 days…

OncologyAdultCancer Researchmedicine.medical_specialtyIndazolesmedicine.medical_treatmentPhases of clinical researchAdministration OralBreast NeoplasmsDrug Administration Schedulechemistry.chemical_compoundBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedEpirubicinPharmacologyChemotherapybusiness.industryLonidamineCancerMiddle Agedmedicine.diseaseMetastatic breast cancerOncologychemistryFemaleCisplatinbusinessProgressive diseaseEpirubicinmedicine.drug
researchProduct